SEC Filing Summary: Abbott Laboratories (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Abbott Laboratories on August 13, 2002. The report serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The filing primarily addresses regulatory compliance requirements under the Sarbanes-Oxley Act of 2002 and SEC Order No. 4-460.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding executive certifications and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing focuses solely on the submission of sworn statements and certifications by the company's top executives.
Guidance, Outlook, and Management Commentary
There is no guidance, outlook, or management commentary regarding future business performance in this filing. The document confirms that Miles D. White (CEO) and Thomas C. Freyman (CFO) submitted sworn statements and certifications pursuant to 18 U.S.C. Section 1350 and Section 906 of the Sarbanes-Oxley Act of 2002.
Key Facts for Investor Verification
- The filing confirms compliance with Sarbanes-Oxley Act certification requirements as of August 13, 2002.
- Exhibits 99.1 through 99.4 contain the sworn statements and certifications of the CEO and CFO.
- This 8-K does not disclose any new financial results, risks, or contingencies.
- Investors should refer to the company's most recent 10-Q or 10-K for actual financial metrics.